Navigation Links
Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy
Date:8/19/2010

er liver metastases compared to chemotherapy alone in order to assess whether the combination should be used as an early intervention for liver tumours.

References and notes

1. Hendlisz A, Van den Eynde M, Peeters M et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. Journal of Clinical Oncology 2010; 28: 3687-3694.

2. The clinical trial was conducted at the following hospitals: - Institut Jules Bordet, Brussels, Belgium - Universitair Ziekenhuis Gent, Gent, Belgium - University Hospital Gasthuisberg, Leuven, Belgium
'/>"/>

SOURCE Sirtex
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
2. YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study
3. Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108
4. New England Journal of Medicine Publishes Data from Pivotal Phase 3 PROVENGE IMPACT Study
5. Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients
6. Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
7. Fulton Project Advances to Phase 2 of Loan Guarantee Process
8. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
9. ChemoCentryx Reports Positive Phase I Study Results for CCX354 at the Annual European Congress of Rheumatology (EULAR)
10. PRA International Opens Phase I Unit in Budapest
11. Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... August 31, 2014 The Global ... professional and in-depth study on the current state ... and China. , The report provides a basic ... industry chain structure. Global market analysis and Chinese ... on history, developments, trends and competitive landscape of ...
(Date:8/29/2014)... 2014 The global companion diagnostics ... 2019. It is expected to grow at a ... was valued at $1.8 billion in 2013, according ... Research. , For more information regarding analysis details ... The research report, titled “Companion Diagnostics Market (Breast ...
(Date:8/29/2014)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the six months ended June 30, 2014. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... , Announced top-line results related to the eight ... enrolled in the Phase 2 iDEAL Study evaluating ...
(Date:8/29/2014)... 29, 2014 Due to a misstatement posted ... the Adult Stem Cell Technology Center, LLC ( ASCTC ) ... cell therapy research that might benefit ALS patients. Because ... new stem cell technologies and therapeutic applications, FRC listed ASCTC ... Challenge donors who wish not to support research that ...
Breaking Biology Technology:Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 2Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 3Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3
... BEIJING, Aug. 30, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: ... in China, announced today that Dr. Weidong Yin, President and ... Helen Yang, Investor Relations Manager, are scheduled to attend four ... Rodman & Renshaw Annual Global Investment Conference, New ...
... ProteinSimple today introduced a revolutionary new system for protein analysis, ... complete reinvention of the Western Blot, and is truly a ... 30 years, researchers have access to a completely automated, walk-away ... was invented in 1979 and to this day remains the ...
... Technologies Corporation (NASDAQ: LIFE ) today announced ... Sciences Conference on Tuesday, September 20 at 8:00am ET. ... will present on behalf of the company. The company ... three weeks following the conference on the Life Technologies, ...
Cached Biology Technology:Sinovac to Participate in Four Investor Conferences in September 2011 2ProteinSimple Reinvents the Western Blot 2Life Technologies to Present at the UBS 2011 Global Life Sciences Conference 2
(Date:9/2/2014)... that digital distribution of media will have lower ... least when file sizes are large. , That,s ... Journal of Industrial Ecology that looked ... such as PlayStation3. Researchers found that Blu-ray Discs ... emissions than game files downloaded over broadband Internet. ...
(Date:9/2/2014)... New research suggests that professional baseball pitchers with poor core ... in a single season because of injury than are pitchers ... and pelvis. , In the study, 347 pitchers were assessed ... in their pelvis as they raised a leg to step ... at least 30 days cumulative, not consecutive during ...
(Date:9/2/2014)... September issue of The FASEB Journal , ... diagnose the leading cause of blindness in adults, ... This advance involves quantifying the early molecular changes ... vessels. Using new probes developed by scientists, they ... of diabetic retinopathy. , "My goal is to ...
Breaking Biology News(10 mins):In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3Molecular probes permit doctors to detect diabetic retinopathy before vision fails 2
... a team led by researchers from Caltech has for ... of chemoreceptorsthe receptors that sense and respond to chemical ... specific architecture is the same throughout a wide variety ... stable, universal structure that has been conserved over evolutionary ...
... new university/industry network to pursue the development of biomaterials, ... increasing incidence of eye disease. The 20/20: NSERC ... as part of the Natural Sciences and Engineering Research ... Minister of State (Science and Technology) Gary Goodyear today ...
... cell researcher Treena Livingston Arinzeh will discuss current stem cell ... for bone fracture and osteoarthritis treatments, spinal cord repair, and ... The event will be held Sept. 29, 2009, at ... floor of the NJIT Campus Center. The ...
Cached Biology News:Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells 2Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells 3Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells 4New research network at McMaster aims to build a better eye 2
4-Hydroxy-3-iodo-5-nitrophenylacetyl hapten is conjugated to BSA protein through lysine by amide bonds....
...
EoProbe Eosinophil Staining Kit, 1 Kit...
... ELISA Development kit contains the basic components ... to measure natural and recombinant rat L-Selectin ... Each kit contains sufficient materials to run ... that the following conditions are met: ...
Biology Products: